PDL BioPharma Rises On Better-than-seen Outlook
- Loading Comments...
NEW YORK (AP) — Shares of PDL BioPharma Inc. jumped Monday after the company said it expects a revenue boost in the second quarter from royalties on a mix of drugs, including the blockbuster cancer treatment Avastin and respiratory virus drug Synagis.
The biotechnology stock gained 22 cents, or 3.1 percent, to reach $7.38 in morning trading. Shares have traded between $5.20 and $12.70 over the last 52 weeks.
The Incline Village, Nev.-based company expects revenue of about $125 million during the quarter, up 18 percent from $106 million a year prior. Analysts polled by Thomson Reuters expect revenue of $114.7 million, on average. ...
Recent Comments
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note | |
|---|---|---|---|---|
| 10,405.83 | 1,102.35 | 2,190.86 | 34.82 |
Oil *
71.98
|
|
UP
68.78
|
UP
6.41
|
UP
7.13
|
UP
0.59
|
10 Yr
3.48%
SPDR Gold
110.82
|
|
+0.67%
|
+0.58%
|
+0.33%
|
+1.72%
|
Data delayed 20 minutes |


Connect with TheStreet